Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|September 2, 2015
Counseling Points Pharmacists Can Provide to Patients on COPD Medications
Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses some counseling points pharmacists can provide to patients on COPD medications.
Advertisement
Kimberly Henderson, MD, JD, medical director for the Health Systems Alliance at CVS Health and regional medical director for MinuteClinic, discusses some counseling points pharmacists can provide to patients on COPD medications.
This video was recorded at the 2015 Convenient Healthcare and Pharmacy Collaborative.
Advertisement
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
From Evidence to Execution: Pharmacists Navigate MRA Selection and Access in HFpEF and HFmrEF
5